Critical Limb Ischemia - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 145
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C3216347D5CEN
Leaflet:

Download PDF Leaflet

Critical Limb Ischemia - Pipeline Review, H2 2016
Critical Limb Ischemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia – Pipeline Review, H2 2016, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 11, 4, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Critical Limb Ischemia.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Critical Limb Ischemia Overview
Therapeutics Development
Pipeline Products for Critical Limb Ischemia - Overview
Pipeline Products for Critical Limb Ischemia - Comparative Analysis
Critical Limb Ischemia - Therapeutics under Development by Companies
Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes
Critical Limb Ischemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Critical Limb Ischemia - Products under Development by Companies
Critical Limb Ischemia - Products under Investigation by Universities/Institutes
Critical Limb Ischemia - Companies Involved in Therapeutics Development
AnGes MG, Inc.
Apceth GmbH & Co. KG
Athersys, Inc.
BiogenCell Ltd.
Caladrius Biosciences Inc
Cynata Therapeutics Limited
Hemostemix Ltd
Histocell S.L.
ID Pharma Co., Ltd.
Integene International Holdings LLC
Juventas Therapeutics, Inc.
Kasiak Research Private Limited
Kowa Company, Ltd.
Neurofx, Inc.
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
ReNeuron Group Plc
Symic Biomedical, Inc.
Targazyme, Inc.
TikoMed AB
U.S. Stem Cell, Inc.
Vericel Corporation
VESSL Therapeutics Ltd
ViroMed Co Ltd
Critical Limb Ischemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AdipoCell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alecmestencel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASCT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-CLI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FAB-117HC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ixmyelocel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MultiGeneAngio - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NFx-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-104 NP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05285401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Refacell-CLI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rejuveinix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReN-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cardiovacular Diseases and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TZ-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Critical Limb Ischemia - Dormant Projects
Critical Limb Ischemia - Discontinued Products
Critical Limb Ischemia - Product Development Milestones
Featured News & Press Releases
Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada
Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia
Apr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles
Apr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia
Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study
Dec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States
Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa
Sep 14, 2015: Hemostemix Executes Strategic Alliance with Hemostemix Asia for Expansion of Phase-2 Clinical Trial to Taiwan
Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia
Aug 10, 2015: Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States
Jul 27, 2015: Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia
Jun 25, 2015: Hemostemix Enrolls Fifth Participant at Vancouver General Hospital in International Phase-2 Clinical Trial for Critical Limb Ischemia
Jun 18, 2015: Hemostemix Prepares Investigational New Drug Application for Review by U.S. Food and Drug Administration for Company’s ACP-01 Formulation to Treat Critical Limb Ischemia
May 19, 2015: Hemostemix Receives Notice of Allowance for Additional U.S. Patent on ACP-01 Covering Autologous Cell Therapy for Critical Limb Ischemia
Apr 20, 2015: Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


LIST OF TABLES

Number of Products under Development for Critical Limb Ischemia, H2 2016
Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H2 2016
Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2016
Critical Limb Ischemia - Pipeline by Athersys, Inc., H2 2016
Critical Limb Ischemia - Pipeline by BiogenCell Ltd., H2 2016
Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H2 2016
Critical Limb Ischemia - Pipeline by Cynata Therapeutics Limited, H2 2016
Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H2 2016
Critical Limb Ischemia - Pipeline by Histocell S.L., H2 2016
Critical Limb Ischemia - Pipeline by ID Pharma Co., Ltd., H2 2016
Critical Limb Ischemia - Pipeline by Integene International Holdings LLC, H2 2016
Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2016
Critical Limb Ischemia - Pipeline by Kasiak Research Private Limited, H2 2016
Critical Limb Ischemia - Pipeline by Kowa Company, Ltd., H2 2016
Critical Limb Ischemia - Pipeline by Neurofx, Inc., H2 2016
Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2016
Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2016
Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H2 2016
Critical Limb Ischemia - Pipeline by Symic Biomedical, Inc., H2 2016
Critical Limb Ischemia - Pipeline by Targazyme, Inc., H2 2016
Critical Limb Ischemia - Pipeline by TikoMed AB, H2 2016
Critical Limb Ischemia - Pipeline by U.S. Stem Cell, Inc., H2 2016
Critical Limb Ischemia - Pipeline by Vericel Corporation, H2 2016
Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H2 2016
Critical Limb Ischemia - Pipeline by ViroMed Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Critical Limb Ischemia - Dormant Projects, H2 2016
Critical Limb Ischemia - Dormant Projects (Contd..1), H2 2016
Critical Limb Ischemia - Discontinued Products, H2 2016 134

LIST OF FIGURES

Number of Products under Development for Critical Limb Ischemia, H2 2016
Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ischemia - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 223 pages

Ask Your Question

Critical Limb Ischemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: